申请人:Emisphere Technologies, Inc.
公开号:EP2409569A2
公开(公告)日:2012-01-25
The invention encompasses formulations that demonstrate the feasibility of oral absorption comprising GLP-1 compounds and specified delivery agents.
本发明包括能证明口服吸收 GLP-1 化合物和特定给药剂可行性的制剂。